RIBOLIFE-B Advances Core siRNA Therapy: Submits Phase 2b European Trial Application for Vortosiran in Venous Thromboembolism

Bulletin Express05-11

Suzhou Ribo Life Science Co., Ltd. (RIBOLIFE-B) has filed a Phase 2b clinical-trial application (CTA) with the European Medicines Agency for vortosiran (RBD4059), its lead small-interfering RNA (siRNA) therapy aimed at preventing venous thromboembolism (VTE).

The submission forms part of a broader clinical program that will evaluate vortosiran across several thromboembolic cardiovascular indications. VTE affects an estimated 10 million patients globally each year and remains a leading cause of cardiovascular morbidity and mortality; existing anticoagulants are often under-utilised or discontinued due to bleeding risks.

Vortosiran targets factor XI (FXI), aiming for selective and durable inhibition of the FXI-mediated coagulation pathway to reduce clotting activity while mitigating bleeding concerns. According to the company, vortosiran is the most advanced siRNA-based FXI inhibitor in clinical development. A Phase 2a study in coronary artery disease in Europe has been completed, and a separate Phase 2b CTA for atrial fibrillation was filed with the EMA in April 2026.

Management cautions that vortosiran may ultimately not achieve successful development or commercialisation. Shareholders and prospective investors are advised to exercise caution when dealing in the company’s shares.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1156882324?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-11 17:44","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1156882324","market":"hk","top_or_hot":-1,"title":"RIBOLIFE-B Advances Core siRNA Therapy: Submits Phase 2b European Trial Application for Vortosiran in Venous Thromboembolism","media":"Bulletin Express","content":"<p>Suzhou Ribo Life Science Co., Ltd. (RIBOLIFE-B) has filed a Phase 2b clinical-trial application (CTA) with the European Medicines Agency for vortosiran (RBD4059), its lead small-interfering RNA (siRNA) therapy aimed at preventing venous thromboembolism (VTE).</p>\n<p>The submission forms part of a broader clinical program that will evaluate vortosiran across several thromboembolic cardiovascular indications. VTE affects an estimated 10 million patients globally each year and remains a leading cause of cardiovascular morbidity and mortality; existing anticoagulants are often under-utilised or discontinued due to bleeding risks.</p>\n<p>Vortosiran targets factor XI (FXI), aiming for selective and durable inhibition of the FXI-mediated coagulation pathway to reduce clotting activity while mitigating bleeding concerns. According to the company, vortosiran is the most advanced siRNA-based FXI inhibitor in clinical development. A Phase 2a study in coronary artery disease in Europe has been completed, and a separate Phase 2b CTA for atrial fibrillation was filed with the EMA in April 2026.</p>\n<p>Management cautions that vortosiran may ultimately not achieve successful development or commercialisation. Shareholders and prospective investors are advised to exercise caution when dealing in the company’s shares.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>RIBOLIFE-B Advances Core siRNA Therapy: Submits Phase 2b European Trial Application for Vortosiran in Venous Thromboembolism</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRIBOLIFE-B Advances Core siRNA Therapy: Submits Phase 2b European Trial Application for Vortosiran in Venous Thromboembolism\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-05-11 17:44</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Suzhou Ribo Life Science Co., Ltd. (RIBOLIFE-B) has filed a Phase 2b clinical-trial application (CTA) with the European Medicines Agency for vortosiran (RBD4059), its lead small-interfering RNA (siRNA) therapy aimed at preventing venous thromboembolism (VTE).</p>\n<p>The submission forms part of a broader clinical program that will evaluate vortosiran across several thromboembolic cardiovascular indications. VTE affects an estimated 10 million patients globally each year and remains a leading cause of cardiovascular morbidity and mortality; existing anticoagulants are often under-utilised or discontinued due to bleeding risks.</p>\n<p>Vortosiran targets factor XI (FXI), aiming for selective and durable inhibition of the FXI-mediated coagulation pathway to reduce clotting activity while mitigating bleeding concerns. According to the company, vortosiran is the most advanced siRNA-based FXI inhibitor in clinical development. A Phase 2a study in coronary artery disease in Europe has been completed, and a separate Phase 2b CTA for atrial fibrillation was filed with the EMA in April 2026.</p>\n<p>Management cautions that vortosiran may ultimately not achieve successful development or commercialisation. Shareholders and prospective investors are advised to exercise caution when dealing in the company’s shares.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"06938","symbol_name":"瑞博生物-B","start_time":0,"source_url":"","article_id":"1156882324","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1156882324","pubTimestamp":1778492646,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Suzhou Ribo Life Science Co., Ltd. (RIBOLIFE-B) has filed a Phase 2b clinical-trial application (CTA) with the European Medicines Agency for vortosiran (RBD4059), its lead small-interfering RNA...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"06938":"瑞博生物-B"},"translate_title":"RIBOLIFE-B推进核心siRNA疗法：提交Vortosiran治疗静脉血栓栓塞症的2b期欧洲试验申请","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"06938":1},"content_text":"Suzhou Ribo Life Science Co., Ltd. (RIBOLIFE-B) has filed a Phase 2b clinical-trial application (CTA) with the European Medicines Agency for vortosiran (RBD4059), its lead small-interfering RNA (siRNA) therapy aimed at preventing venous thromboembolism (VTE).\nThe submission forms part of a broader clinical program that will evaluate vortosiran across several thromboembolic cardiovascular indications. VTE affects an estimated 10 million patients globally each year and remains a leading cause of cardiovascular morbidity and mortality; existing anticoagulants are often under-utilised or discontinued due to bleeding risks.\nVortosiran targets factor XI (FXI), aiming for selective and durable inhibition of the FXI-mediated coagulation pathway to reduce clotting activity while mitigating bleeding concerns. According to the company, vortosiran is the most advanced siRNA-based FXI inhibitor in clinical development. A Phase 2a study in coronary artery disease in Europe has been completed, and a separate Phase 2b CTA for atrial fibrillation was filed with the EMA in April 2026.\nManagement cautions that vortosiran may ultimately not achieve successful development or commercialisation. Shareholders and prospective investors are advised to exercise caution when dealing in the company’s shares.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation,SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.3","shortVersion":"4.42.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1156882324","isCrawlerRequest":true}